Skip to Content

Tonix Pharmaceuticals Holding Corp TNXP

Morningstar Rating
$0.17 0.00 (2.75%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

TNXP is trading at a 55% discount.
Price
$0.17
Fair Value
$7.47
Uncertainty
Extreme
1-Star Price
$6.35
5-Star Price
$6.16
Economic Moat
Nylm
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if TNXP is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$0.17
Day Range
$0.160.18
52-Week Range
$0.163.69
Bid/Ask
$0.17 / $0.17
Market Cap
$14.36 Mil
Volume/Avg
69,962 / 2.2 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
0.41
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix’s development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
103

Valuation

Metric
TNXP
Price/Earnings (Normalized)
Price/Book Value
0.10
Price/Sales
0.41
Price/Cash Flow
Price/Earnings
TNXP

Financial Strength

Metric
TNXP
Quick Ratio
1.56
Current Ratio
2.53
Interest Coverage
Quick Ratio
TNXP

Profitability

Metric
TNXP
Return on Assets (Normalized)
−62.43%
Return on Equity (Normalized)
−72.46%
Return on Invested Capital (Normalized)
−71.11%
Return on Assets
TNXP
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRCcgbzwxlfSybv$558.5 Bil
VRTX
Vertex Pharmaceuticals IncTlyqvxncSbtmcf$103.4 Bil
REGN
Regeneron Pharmaceuticals IncNkrdylycdZklwzp$102.8 Bil
MRNA
Moderna IncPdlpwjwlRlqdf$41.0 Bil
BNTX
BioNTech SE ADRMwyrzscsmKcyh$21.7 Bil
ALNY
Alnylam Pharmaceuticals IncWkqblzmhbTbpytp$19.7 Bil
BMRN
Biomarin Pharmaceutical IncJxjnptbDchhswr$17.4 Bil
RPRX
Royalty Pharma PLC Class AFmpqbnxvzTyfsl$13.0 Bil
INCY
Incyte CorpScqtmdqTyjxjs$12.4 Bil
UTHR
United Therapeutics CorpZjszlxpnnRjf$11.2 Bil

Sponsor Center